Mumps Vaccine Market Analysis and Forecast to 2032: By Age Group (Pediatric, Adult), Distribution Channel (Hospitals & Clinics, Vaccination Centers), and Region

Mumps Vaccine Market Analysis and Forecast to 2032: By Age Group (Pediatric, Adult), Distribution Channel (Hospitals & Clinics, Vaccination Centers), and Region

The global mumps vaccine market was valued at USD 2.0 billion in 2022 and it is anticipated to grow further till USD 3,7 billion by 2032, at a CAGR of 6.4% during the forecast period.

The immunizations used to prevent the mumps virus infection are known as mumps vaccines. The MMR vaccine, which is administered intravenously, is the vaccine of choice to protect against mumps infection. The live attenuated viruses of the three illnesses are used in this injection-based vaccine. Children under the age of 12 months and adults who are not at a high risk of exposure and transmission receive one dose of the MMR vaccination. Children between the ages of 2 and 18 as well as adults who run the risk of contracting the mumps are advised to have two doses of the vaccine.
Global Mumps Vaccine Market Scope and Report Structure
Market Driver & Trends
Due to the large number of customers who are health-conscious, the pharmaceutical sector is growing and innovating to produce vaccines, which opens up opportunities for the mumps vaccine market to expand. The availability of increasing healthcare infrastructure, an increase in unmet healthcare demands, an increase in the occurrence of infectious diseases like the mumps diseases, and a surge in demand for mumps vaccines are all predicted to contribute to the growth of the mumps vaccine market.

Furthermore, the desire for better healthcare services, considerable government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the global market for measles vaccines.
Market Restraints and Challenges
Even though the market for mumps vaccines has grown as a result of several favourable factors, the industry's expansion is being hampered by factors like strict laws and regulations governing vaccine research, high production costs, and a difficult manufacturing procedure. Access to different vaccines is hampered in many countries by high development costs and inadequate production capacity. Additionally, biological goods like vaccines are created from living things whose complex molecular structures may be recognised through physical or chemical means. Additionally, the market is constrained by the inherent diversity of living organisms, the potential for material contamination by chemicals or the environment, and the necessity for specific quality assurance and control processes.

Global Mumps Vaccine Market Segmental Overview
The report analyses the global mumps vaccine market based on the age group, distribution channel, and region.

Global Mumps Vaccines Market by Age Group

Based on the age group, it is segmented into pediatric, and adult. The pediatric segment is anticipated to dominate the market during the forecast period. Similarly, the adult segment is anticipated to witness the various opportunities during the forecast period.

Global Mumps Vaccines Market by Distribution Channel

Based on distribution channel, it is segmented into hospitals & clinics, and vaccination centers. The hospitals & clinics segment is anticipated to dominate the market during the forecast period. Similarly, vaccination centers segment is anticipated to witness the fastest growth during the forecast period.
Geographical Analysis of the Global Mumps Vaccines Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is anticipated to dominate the market during the forecast period. Similarly, Asia Pacific region is anticipated to witness the fastest growth during the forecast period.
Major Players in the Global Mumps Vaccines Market
The key players studied in the report are MedImmune, Johnson & Johnson, Merck & Co., Inc., Sanofi, Serum Institute of India, Bavarian Nordic, Astellas Pharma India, CSL Limited, Emergent BioSolutions, and GlaxoSmithKline among others.
COVID-19 Impact
The global mumps vaccination market is expected to experience a decline due to the COVID-19 outbreak. Immunization is one of the most effective public health measures for the prevention of disease, which has decreased in recent years, according to the World Health Organization (WHO). Global vaccination rates have decreased as a result of the COVID-19 pandemic and related illnesses, and 25 million children will not have had their vaccinations in 2021. Additionally, COVID-19 has endangered campaigns to raise awareness of viral illnesses including the mumps, measles, and rubella as a result of the healthcare industry focusing its resources and attention on COVID-19. Additionally, the government's support for vaccination campaigns and financing decreased as a result of the increased funding for COVID-19.
Recent Developments

June 2022, GlaxoSmithKline plc announced the US FDA approval of Priorix for the prevention of measles, mupms, and rubella in individuals 12 months of age and older, thereby expanding its offering in U.S. and also enhancing its product portfolio for vaccines.

Frequently Asked Questions
Q1. How big is the Mumps Vaccine market?

Ans. The global Mumps Vaccine market size was USD 2.0 billion in 2022 and it is anticipated to grow further till USD 3,7 billion by 2032, at a CAGR of 6.4% from 2023 to 2032.

Q2. What is the Mumps Vaccine market growth rate?

Ans. The growth rate of the Mumps Vaccine market is 6.4%.

Q3. Which region holds a major market share for the Mumps Vaccine market?

Ans. North America holds a major market share of the Mumps Vaccine market in 2022.

Q4. Which segment accounted for the largest Mumps Vaccine market share?

Ans. By age group, pediatric segment accounted for the largest Mumps Vaccine market share.

Q5. Who are the key players in the Mumps Vaccine market?

Ans. The global Mumps Vaccine market report includes players such as MedImmune, Johnson & Johnson, Merck & Co., Inc., Sanofi, Serum Institute of India, Bavarian Nordic, Astellas Pharma India, CSL Limited, Emergent BioSolutions, and GlaxoSmithKline among others.

Q6. What are the factors driving the Mumps Vaccine market growth?

Ans. The major factors driving the growth of the market are the growing market in emerging countries.

Q7. What are the key growth strategies of Mumps Vaccine market players?

Ans. The key growth strategies of Mumps Vaccine market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Mumps Vaccine market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Mumps Vaccine market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.